Xenon Pharmaceuticals Inc

Healthcare · Biotechnology

36.40$ +0.8% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

Xenon Pharmaceuticals Inc (XENE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,296 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet XENE
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	73	67	61	54	46	46	38	65	130	122	115	106	99	148	237	211	199	189	291	275	264	572	558	807	776	754	720	685	671	965	919	884	836	798	743	674	608	982	1,387	1,296
Current Assets	71	66	59	53	45	45	37	64	129	121	112	103	96	145	234	207	195	182	283	267	256	559	546	795	649	600	533	545	531	645	707	728	660	635	566	500	480	561	1,107	946
Cash	54	17	20	23	15	20	17	47	88	68	52	37	38	25	61	44	15	45	88	83	88	176	117	370	103	57	70	65	100	149	59	137	88	143	117	135	105	199	546	120
Cash & Short-Term Investments	69	64	58	52	44	44	35	63	127	119	110	102	95	141	230	203	191	177	275	261	250	552	538	788	638	592	527	540	527	638	700	722	654	627	550	488	462	549	1,095	931
Receivables	0.6	0.2	0.2	0.2	0.1	0.4	0.4	0.2	0.2	0.3	0.1	0.2	0.2	0.8	1.6	1.8	1.6	1.8	5.1	2.9	3.2	2.8	2.9	2.5	2.5	1.0	2.2	2.1	0.8	0.9	0.8	0.9	0.9	1.5	8.6	1.1	0.8	1.4	1.2	1.6
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	0.0	–	0.0	-1.8	–	–	0.0	0.0	–	0.0	0.0	0.0	0.0	-1.0	0.0	-2.1	-0.8	0.0	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	1.5	1.4	1.4	1.3	1.2	1.1	1.1	1.1	1.0	1.0	1.2	1.3	1.2	1.7	3.0	2.3	3.0	3.6	3.7	7.4	4.3	4.5	4.3	4.5	4.6	6.5	8.0	19	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	4.1	3.6	3.6	3.8	3.1	10	9.3	15	19	19	22	23	24	56	49	21	17	18	14	18	15	22	16	22	23	33	33	38	35	37	31	40	38	43	39	40	48	400	49	53
Current Liabilities	4.0	3.5	3.6	3.8	3.1	4.1	3.8	3.1	4.4	4.1	6.4	9.3	12	43	49	21	17	15	11	15	13	14	8.0	14	16	23	22	28	25	27	22	31	30	36	32	33	38	42	40	45
Short-Term Debt	–	–	–	–	–	0.7	1.4	12	15	15	0.6	2.7	3.8	4.8	16	0.6	0.6	0.3	0.3	0.8	0.7	0.6	8.2	7.9	7.2	0.5	1.2	1.2	1.2	1.3	1.3	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.6	1.3
Accounts Payable	0.5	1.5	1.2	1.3	0.8	1.3	0.5	0.9	1.0	0.7	1.1	1.5	1.4	2.5	3.2	1.6	2.2	3.0	2.1	3.3	3.1	3.8	1.7	3.2	3.1	8.5	11	12	6.1	8.6	6.4	9.5	5.4	5.1	6.9	4.8	4.6	3.9	5.7	2.5
Long-Term Debt	0.0	0.0	0.0	0.0	0.0	6.1	5.5	12	15	15	15	13	12	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	69	64	57	50	43	36	28	51	111	103	92	83	75	92	188	189	182	171	276	257	249	550	542	786	753	721	687	646	637	928	888	844	798	755	704	634	560	582	1,338	1,242
Retained Earnings	-137	-143	-150	-158	-165	-173	-177	-185	-199	-208	-219	-229	-238	-250	-257	-257	-266	-278	-294	-316	-332	-357	-377	-408	-445	-483	-524	-572	-620	-665	-713	-771	-834	-899	-965	-1,049	-1,140	-1,245	-1,348	-1,458
Shares Outstanding	15	18	18	18	18	18	18	14	20	26	26	26	26	33	33	35	35	37	37	42	42	41	55	56	65	66	66	66	66	70	78	78	78	78	79	79	79	79	87	100

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings